Those of you who are keeping up to date will have no doubt heard about Ticagrelor, a new antiplatelet drug. Below are key points regarding this revolutionary drug
Mechanism of action - Reversible platelet ADP receptor blocker (P2Y12)
Unlike Clopidogrel, it is not a thienopyridine drug.
Advantages over Clopidogrel include a more rapid onset of action and its platelet inhibition is more pronounced. Bleeding risks are not different from Clopidogrel either.
From the MRCP point of view
1. Its a reversible P2Y12 inhibitor
2. More rapid onset of action compared with clopidogrel
3. More potent platelet inhibition.
There are recent studies looking at the role of Ticagrelor in ACS. The NEJM published the PLATO study that compared Ticagrelor and Clopidogrel in patients with ACS. The primary end points were significantly reduced. Interestingly, dyspnoea was a side effect seen more often with Ticagrelor.
It is a good idea to know what this study involved. Read the study here.
Pharmacology is a big part of the MRCP part 1 exam. Read a good book and thou shalt pass! Here are a few
Mechanism of action - Reversible platelet ADP receptor blocker (P2Y12)
Unlike Clopidogrel, it is not a thienopyridine drug.
Advantages over Clopidogrel include a more rapid onset of action and its platelet inhibition is more pronounced. Bleeding risks are not different from Clopidogrel either.
From the MRCP point of view
1. Its a reversible P2Y12 inhibitor
2. More rapid onset of action compared with clopidogrel
3. More potent platelet inhibition.
There are recent studies looking at the role of Ticagrelor in ACS. The NEJM published the PLATO study that compared Ticagrelor and Clopidogrel in patients with ACS. The primary end points were significantly reduced. Interestingly, dyspnoea was a side effect seen more often with Ticagrelor.
It is a good idea to know what this study involved. Read the study here.
Pharmacology is a big part of the MRCP part 1 exam. Read a good book and thou shalt pass! Here are a few
Enjoy!
No comments:
Post a Comment